Figure 6

AMPK attenuated resistin-increased SK-Hep1 cell adhesions to HUVECs through activating the NF-κB. (A) SK-Hep1 cells were kept as the control or treated with resistin (50 ng/mL) for 1, 2 and 4 h. (B) SK-Hep1 cells were kept as the control pretreated with DMSO or NF-κB inhibitors, PDTC or SN50, to inhibit activity. They were then treated with resistin (50 ng/mL) for 4 h. (C) SK-Hep1 cells were kept as the control or pretreated with AICAR at different concentrations (i.e. 0, 0.1, 0.5 and 1 ng/ml) for 1 h and then kept as the control or treated with resistin (50 ng/mL) for 4 h. (D) SK-Hep1 cells were treated with resistin (50 ng/mL) or AICAR at different concentrations (i.e. 0, 0.1, 0.5 and 1 ng/ml) for 4 h. *, P < 0.05 vs. control cells. #, P < 0.05 vs. cells treated with resistin only.